1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine

• ChemBase ID: 224
• Molecular Formular: C20H23NS
• Molecular Mass: 309.46832
• Monoisotopic Mass: 309.15512074
• SMILES: S1c2c(C(CC3CCCN(C3)C)c3c1cccc3)cccc2
• Canonical SMILES: CN1CCCC(C1)CC1c2ccccc2Sc2c1cccc2
• InChI: InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3
• InChIKey: MJFJKKXQDNNUJF-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine
• IUPAC Traditional name: metixene
• Brand Name: Atosil; Contalyl; Methixart; Tremaril; Tremaril hydrochloride; Tremonil; Trest
• Synonyms: Methixen [German]; Methixene; Methixene hydrochloride; Metisene [DCIT]; Metixene hydrochloride; Metixeno [INN-Spanish]; Metixenum [INN-Latin]; Metixene

Database IDs

• CAS Number: 4969-02-2
• PubChem SID: 160963687; 46508970
• PubChem CID: 4167

CALCULATED PROPERTIES

JChem

• H Acceptors: 1
• H Donor: 0
• LogD (pH = 5.5): 1.7270386
• LogD (pH = 7.4): 3.1309526
• Log P: 5.0647764
• Molar Refractivity: 97.1684 cm^3
• Polarizability: 37.758297 Å^3
• Polar Surface Area: 3.24 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 5.51
• LOG S: -6.48
• Solubility (Water): 1.02e-04 g/l

PROPERTIES

Physical Property

• Solubility: Soluble as HCl salt
• Hydrophobicity(logP): 4.7

DETAILS

DrugBank - DB00340

• Drug Groups: approved
• Description: Metixene (or methixene) is a anticholinergic used as an anti-parkinson drug. [Wikipedia]
• Indication: Used for the symptomatic treatment of parkinsonism.
• Pharmacology: Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.
• Toxicity: Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Metabolism occurs via sulfoxydation and N-demethylation.
• Absorption: Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.
• References: [Link]
• External Links: Wikipedia

REFERENCES

• Link